Comparing Trials Studying Treatment Intensification In mHSPC

EP: 1.An Overview of the ARANOTE Trial

Now Viewing

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Comparative Analysis With Other mHSPC Trials

Key Themes:

• Comparison between ARANOTE and other intensification trials (ARCHES, TITAN, LATITUDE)
• Differences in patient populations and trial design
• Unique attributes of various androgen receptor pathway inhibitors

Expert Insights:

• Dr Shore compared darolutamide's performance in ARANOTE to other agents: enzalutamide (ARCHES), apalutamide (TITAN), and abiraterone (LATITUDE).

While all agents demonstrated benefit when combined with androgen deprivation therapy, Dr Shore noted important differences in adverse effect profiles, tolerability, and patterns of adoption in clinical practice.